Lyell Immunopharma, Inc. Equity Securities, FV-NI, Unrealized Gain
Lyell Immunopharma, Inc. (LYEL) reported Equity Securities, FV-NI, Unrealized Gain of $30.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2025-03-11
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain for the quarter ending 2024-12-31 was -$17.00K.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain for the quarter ending 2024-09-30 was -$102.00K.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain for the quarter ending 2024-06-30 was -$1.39M.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain for the quarter ending 2024-03-31 was $1.53M.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain for fiscal 2024 was $30.00K.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain for fiscal 2023 was $0.00.
- Lyell Immunopharma, Inc. equity securities, fv-ni, unrealized gain for fiscal 2022 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain 3 month | Equity Securities, FV-NI, Unrealized Gain 6 month | Equity Securities, FV-NI, Unrealized Gain 9 month | Equity Securities, FV-NI, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$119.00K derived: sum of 2 quarters · filed 2025-03-11 | -$1.50M derived: sum of 3 quarters · filed 2025-03-11 | $30.00K 10-K · filed 2025-03-11 |
| 2024-09-30 | -$102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.49M derived: sum of 2 quarters · filed 2024-11-07 | $47.00K 10-Q · filed 2024-11-07 | $47.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-06-30 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $149.00K 10-Q · filed 2024-08-07 | $149.00K derived: sum of 3 quarters · filed 2025-03-11 | $149.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | $1.53M 10-Q · filed 2024-05-06 | $1.53M derived: sum of 2 quarters · filed 2025-03-11 | $1.53M derived: sum of 3 quarters · filed 2025-03-11 | $1.53M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $0.00 derived: sum of 3 quarters · filed 2025-03-11 | $0.00 10-K · filed 2025-03-11 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |